Harry P. Erba, MD, PhD, Duke University School of Medicine
Articles
The Role of Venetoclax for Treatment of AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ;Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ;Daniel Pollyea, MD, MS, University of Colorado Denver;Vinod Pullarkat, MD, City of Hope Medical Center
August 19th 2021Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.
Read More
Future Treatment Landscape of AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
March 15th 2021Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Read More
Maintenance Therapy Post-Transplant in AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
March 15th 2021Patient selection for maintenance therapy post-allogeneic transplant in myeloid malignancies and thoughts on treatment of FLT3-mutated disease post-transplant with agents such as midostaurin.
Read More
Use of APR-246 and Oral HMAs in AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
March 8th 2021Read More
Use of Omidubicel Therapy in Hematologic Malignancies
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
March 1st 2021Read More
BMT CTN 1102 Study in High-Risk MDS
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
March 1st 2021Read More
Novel Targets and Biomarkers in AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
February 22nd 2021Read More
IDH1/2-Mutated Treatment-Naïve AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
February 22nd 2021Read More
BCL2 Inhibition in AML: VIALE-A Study
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
February 15th 2021Read More
Type 1/2 FLT3 Inhibitors in AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
February 15th 2021Read More
Role of Dual Targeted Therapy in AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
February 8th 2021Read More
Sequencing of FLT3 Inhibitors in AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
February 8th 2021Read More
Management of AML: FLT3 Inhibitors and BCL2 Inhibitors
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
February 1st 2021Read More
Role of FLT3 Inhibitors in Chemo-Ineligible AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
February 1st 2021Read More
MRD Monitoring in FLT3 ITD AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
January 25th 2021Read More
Prognostic Significance of IDH Mutations in AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
January 21st 2021Read More
FLT3 Testing for Treatment of AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
January 21st 2021Read More
Molecular Testing in Community Practices
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
January 15th 2021Read More
Role of Molecular Testing in AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Alexander E. Perl, MD, University of Pennsylvania;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center;Adam Bagg, MD, University of Pennsylvania;Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute
January 15th 2021Read More
Progress in the Treatment of AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020Read More
Implications for Treating AML With CC-486
Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020Read More
CC-486 Maintenance Therapy in AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020Read More
CPX-351 in Newly Diagnosed Secondary AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020Read More
Differentiation Syndrome and IDH Inhibitors in AML
Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020Read More
Latest Updated Articles
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: December 17th 2024 | Updated: March 26th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: January 22nd 2025 | Updated: February 14th 2025
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
%20(1).jpg?fit=crop&auto=format)
